title: Reply: Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's Disease in the UK and Germany.
authors.affiliation: a Institute for Pharmaeconomic Research , Health Economics , Vienna , Austria.
authors.forename: Evelyn
authors.initials: E
authors.lastname: Walter
authors.affiliation: a Institute for Pharmaeconomic Research , Health Economics , Vienna , Austria.
authors.forename: Per
authors.initials: P
authors.lastname: Odin
mesh_terms: D000978:Antiparkinson Agents / Q000191:economics* / Q000627:therapeutic use*; D001058:Apomorphine / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D001058:Apomorphine